SSTR2 and MGMT are well-recognized predictive markers for SSA and temozolomide efficacy, respectively, and are commonly discussed in gastroenteropancreatic and pulmonary neuroendocrine tumors [23,24,25,26]. The gene discussed is SSTR2; the disease is lung neuroendocrine neoplasm.